News from immunocellular therapeutics, ltd A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Sep 17, 2014, 06:00 ET
ImmunoCellular Therapeutics Logo.  (PRNewsFoto/ImmunoCellular Therapeutics)

ImmunoCellular Therapeutics Receives Positive Regulatory Feedback on ICT-107 Supporting Advancement to Registrational Phase III Testing in Newly Diagnosed Glioblastoma

 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) provides a corporate update on its plans to advance ICT-107 to a...

Aug 07, 2014, 16:05 ET
ImmunoCellular Therapeutics Logo.  (PRNewsFoto/ImmunoCellular Therapeutics)

ImmunoCellular Therapeutics Announces Second Quarter 2014 Financial Results

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced financial results for the quarter ended June 30, 2014. ...

Jul 29, 2014, 16:01 ET
ImmunoCellular Therapeutics Logo.  (PRNewsFoto/ImmunoCellular Therapeutics)

ImmunoCellular Therapeutics to Report Financial Results for the Second Quarter 2014 on August 7, 2014

 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that it plans to report second quarter 2014 financial...

Jun 01, 2014, 07:30 ET
ImmunoCellular Therapeutics Logo.  (PRNewsFoto/ImmunoCellular Therapeutics)

ImmunoCellular Therapeutics Presents Updated ICT-107 Phase II Data in Patients with Newly Diagnosed Glioblastoma at the 2014 ASCO Annual Meeting

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT:IMUC) announced that updated efficacy and safety data from the phase II trial of...

May 08, 2014, 16:01 ET
ImmunoCellular Therapeutics Logo.  (PRNewsFoto/ImmunoCellular Therapeutics)

ImmunoCellular Therapeutics Announces First Quarter 2014 Financial Results

 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced financial results for the quarter ended March 31,...

May 01, 2014, 06:00 ET
ImmunoCellular Therapeutics Logo.  (PRNewsFoto/ImmunoCellular Therapeutics)

ImmunoCellular Therapeutics to Report Financial Results for the First Quarter 2014 on May 8, 2014

 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that it plans to report first quarter 2014 financial...

Apr 21, 2014, 16:00 ET
ImmunoCellular Therapeutics Logo.  (PRNewsFoto/ImmunoCellular Therapeutics)

ImmunoCellular Therapeutics Announces ICT-107 Phase II Data Abstract Accepted for Oral Presentation at the 2014 ASCO Annual Meeting

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that the abstract describing the Company's phase II trial of...

Mar 13, 2014, 16:00 ET
ImmunoCellular Therapeutics Logo.  (PRNewsFoto/ImmunoCellular Therapeutics)

ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results

 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced financial results for the quarter and year ended...

Mar 11, 2014, 16:15 ET
ImmunoCellular Therapeutics Logo.  (PRNewsFoto/ImmunoCellular Therapeutics)

ImmunoCellular Therapeutics Announces Change to Meeting Date for Annual Meeting of Stockholders

 ImmunoCellular Therapeutics, Ltd. (NYSE MKT: IMUC)  ("ImmunoCellular" or the "Company") today announced that it will hold its 2014...

Mar 04, 2014, 06:00 ET
ImmunoCellular Therapeutics Logo.  (PRNewsFoto/ImmunoCellular Therapeutics)

ImmunoCellular Therapeutics to Report Financial Results for the Fourth Quarter and Full Year 2013 on March 13, 2014

 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that it plans to report fourth quarter and full year...

Mar 03, 2014, 06:00 ET
ImmunoCellular Therapeutics Logo.  (PRNewsFoto/ImmunoCellular Therapeutics)

ImmunoCellular Therapeutics to Present at ROTH Conference on March 11th

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer of...

Feb 25, 2014, 06:00 ET
ImmunoCellular Therapeutics Logo.  (PRNewsFoto/ImmunoCellular Therapeutics)

ImmunoCellular Therapeutics Receives Orphan Drug Status for ICT-107 in Glioblastoma in the European Union

 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) announced that the European Medicines Agency (EMA) has granted orphan...

Feb 14, 2014, 16:00 ET
ImmunoCellular Therapeutics Logo.  (PRNewsFoto/ImmunoCellular Therapeutics)

ImmunoCellular Therapeutics' Founder and Chief Scientific Officer, John Yu, MD, Presents at "Targeting Cancer Stem Cells" Symposium

 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that the Company's Founder and Chief Scientific...

Feb 03, 2014, 06:00 ET
ImmunoCellular Therapeutics Logo.  (PRNewsFoto/ImmunoCellular Therapeutics)

ImmunoCellular Therapeutics to Present at the BIO CEO & Investor Conference on February 10, 2014

 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer, will...

Jan 13, 2014, 06:00 ET
ImmunoCellular Therapeutics Logo.  (PRNewsFoto/ImmunoCellular Therapeutics)

ImmunoCellular Therapeutics Provides Update on 2014 Corporate Strategies and Milestones

 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today provided an update on the Company's anticipated 2014 corporate...

Jan 09, 2014, 16:38 ET
ImmunoCellular Therapeutics Logo.  (PRNewsFoto/ImmunoCellular Therapeutics)

ImmunoCellular Therapeutics Issues Shareholder Letter Providing Update on ICT-107 Program in Newly Diagnosed Glioblastoma

 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today issued the following letter to shareholders providing an update...

Oct 03, 2011, 08:30 ET

NeoStem's Subsidiary, Progenitor Cell Therapy, and ImmunoCellular Therapeutics Enter Into a Manufacturing Agreement

Progenitor Cell Therapy, LLC ("PCT"), an internationally recognized cell therapy services and development company and a wholly-owned subsidiary of...